Innovation for Life
Innovation for Life
Developing next-generation innovative medicines and biosimilars for cancer, autoimmune, cardiovascular, ophthalmic and other serious diseases.
Drugs that change patients' lives
Explore All Products →Our biologic medicines have received approvals in markets including China, the United States and the European Union, spanning autoimmune diseases, oncology and cardiovascular disease.
Science-Driven,
Innovation for Life
Based on Guangzhou International Bio Island, we develop innovative medicines and biosimilars. Multiple products are approved in China, the United States, the EU and other markets.
+ Discover Bio-TheraJoin hands with the world's leading pharmaceutical companies to expand international markets
Explore Partnerships →
Next-Generation Therapies
Explore Our Pipeline →Advancing innovative medicines and biosimilars, with a focus on ADCs and candidates for autoimmune diseases.
Program
Target / Mechanism
Key Indications
Preclinical
Phase I
Phase II
Phase III
Regulatory Submission
Approved
BAT8013
CD25 ADC
advanced solid tumors
BAT2306
IL-17A (secukinumab)
Ankylosing spondylitis / psoriasis
BAT8008
Trop2 ADC
Various solid tumors
Technology
From antibody discovery and engineering to ADCs and commercial manufacturing, our integrated capabilities support the development of innovative medicines and biosimilars.
+ Explore technology platforms
Manufacturing & Quality
A quality management system that meets the GMP requirements of the United States, the European Union, and China has been established. The company has built an industrialization base that complies with China's NMPA, US FDA, European EMA and Brazilian ANVISA standards.
Based on the ICH Q10 model, quality management spans research and development, technology transfer, commercial production and product discontinuation.
+ Explore furtherCompany News
+ Read all news-
August 18, 2026
Bio-Thera and Avalon Pharma deepen collaboration on BAT2406 (dupilumab) in Saudi Arabia and other MENA markets
-
July 23, 2026
Phase I clinical study of Bio-Thera's innovative drug BAT8013 (CD25 ADC) for the treatment of advanced or metastatic solid tumors has completed the enrollment of the first subject
R&D Updates
+ View all information-
July 21, 2026
European Society for Medical Oncology (ESMO) Annual Congress
BAT8008+BAT1308 latest data released -
July 2, 2026
"Lancet Rheumatology"
BAT2306 phase III clinical study results released
Careers
The company has built a talent team with high academic level, wide professional coverage and strong technical force. Partners interested in antibody drug development and industrialization are welcome to join Bio-Thera.
